JCR Pharmaceuticals Co., Ltd and Sumitomo Pharma Co., Ltd. announced that they have concluded a co-promotion agreement for Izcargo I.V. Infusion 10 mg. in Japan.
JCR Pharmaceuticals Co., Ltd and Sumitomo Pharma Co., Ltd. announced that they have concluded a co-promotion agreement for Izcargo I.V. Infusion 10 mg (hereinafter, “the Product”) in Japan.
JCR Pharmaceuticals Co., Ltd and Sumitomo Pharma Co., Ltd. announced that they have concluded a co-promotion agreement for Izcargo I.V. Infusion 10 mg (hereinafter, “the Product”) in Japan.
This is a recombinant therapeutic for mucopolysaccharidosis type II currently sold by JCR.From April 24, 2023, JCR and Sumitomo Pharma will jointly engage in information dissemination activities for the Product to healthcare professionals. JCR will continue to manufacture and sell the Product.
Sumitomo Pharma will make an upfront payment to JCR upon execution of the Agreement. Sumitomo Pharma will record the consideration for promotion received from JCR as revenue.
The Product is a treatment for mucopolysaccharidosis type II (Hunter syndrome), a type of lysosomal storage disease, developed by JCR. It is the world’s first I.V. infusion to cross the blood-brain barrier. (BBB) and act directly on brain parenchyma cells, through the use of J-Brain Cargo JCR’s BBB penetration technology. The Product can be expected to improve or control not only systemic symptoms but also central nervous system manifestations. JCR has marketed the Product since May 2021 in Japan. Cumulative sales for the third quarter of the fiscal year ending March 31, 2023 were approximately 3.4 billion yen.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins